<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="207881"><TitleDisplay>Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study</TitleDisplay><TitleOfficial>Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02211482</Identifier><Identifier type="Organisational Study">FH-18</Identifier><Identifier type="Trial Acronym">PADDLE</Identifier></Identifiers><Indications><Indication id="159">HIV-1 infection</Indication></Indications><BiomarkerNames><BiomarkerName id="1857" role="Therapeutic effect marker" type="Genomic;Proteomic">T-cell surface glycoprotein CD4</BiomarkerName><BiomarkerName id="1880" role="Therapeutic effect marker" type="Cellular">T-Helper Lymphocytes</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName><BiomarkerName id="44218" role="Therapeutic effect marker" type="Genomic">Human immunodeficiency virus RNA</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>dolutegravir</Name><Drug id="59062">dolutegravir</Drug></Intervention><Intervention type="InterventionPrimary"><Name>lamivudine</Name><Drug id="3474">lamivudine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3474">lamivudine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039482">The Huesped Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1050515">ViiV Healthcare Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="59062">dolutegravir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039482">The Huesped Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1050515">ViiV Healthcare Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3474" type="Drug"><TargetEntity id="184356" type="siDrug">Lamivudine</TargetEntity></SourceEntity><SourceEntity id="59062" type="Drug"><TargetEntity id="466915" type="siDrug">Dolutegravir sodium</TargetEntity></SourceEntity><SourceEntity id="1039482" type="Company"><TargetEntity id="5035542932" type="organizationId">Huesped Foundation</TargetEntity></SourceEntity><SourceEntity id="1050515" type="Company"><TargetEntity id="5035313195" type="organizationId">ViiV Healthcare Ltd</TargetEntity></SourceEntity><SourceEntity id="138" type="Action"><TargetEntity id="416" type="Mechanism">DNA-Directed DNA Polymerase Inhibitors</TargetEntity><TargetEntity id="1065" type="Mechanism">DNA Polymerase Inhibitors</TargetEntity><TargetEntity id="3618" type="Mechanism">Nucleic Acid Polymerase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1039482">The Huesped Foundation</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1050515">ViiV Healthcare Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1016">HIV-1 reverse transcriptase inhibitor</Action><Action id="138">DNA polymerase inhibitor</Action><Action id="1832">Nucleoside reverse transcriptase inhibitor</Action><Action id="551">RNA DNA polymerase inhibitor</Action><Action id="7588">HIV-1 integrase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="747">HIV replication inhibitor</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="630">Stereochemistry</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2014-10-31T00:00:00Z</DateStart><DateEnd type="actual">2017-04-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:48:31Z</DateChangeLast><DateAdded>2014-08-11T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Fundacion Huesped</Affiliation><Email>pedro.cahn@huesped.org.ar</Email><Name>Pedro Cahn, PhD</Name><Phone>5411-49817777</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;gt; 18 years&lt;/li&gt;&lt;li&gt;Documented HIV-1 infection (positive ELISA plus a confirmatory Western Blot; or plasma HIV-1 RNA &gt;/= 10,000 copies/ml)&lt;/li&gt;&lt;li&gt;Voluntarily signed and dated, IRB/IEC approved informed consent form&lt;/li&gt;&lt;li&gt;Agrees not to take any other  medication during the study&lt;/li&gt;&lt;li&gt;Screening HIV RNA&amp;gt; 5000 and  &amp;lt;/= 100,000 copies/ml&lt;/li&gt;&lt;li&gt;Naive to ARV therapies&lt;/li&gt;&lt;li&gt;CD4 &gt;/= 200 cells/ml&lt;/li&gt;&lt;li&gt;Patients can comply with protocol requirements&lt;/li&gt;&lt;li&gt;Patient's general medical condition, in the investigator's opinion, does not interfere with assessments and completion of the trial&lt;/li&gt;&lt;li&gt;Patient is a male or a female not breastfeeding or pregnant&lt;/li&gt;&lt;li&gt;A female, may be eligible if she:&lt;ul&gt;&lt;li&gt;Is of non-child-bearing potential&lt;/li&gt;&lt;li&gt;Is of child-bearing potential with a negative pregnancy test at  screening and day 1 and agrees to use one of the following methods:&lt;ul&gt;&lt;li&gt;Complete abstinence from penile-vaginal intercourse from 2 weeks prior to administration of IP, throughout the study, and for at least 2 weeks after&lt;/li&gt;&lt;li&gt;Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide)&lt;/li&gt;&lt;li&gt;IUD  and male condom&lt;/li&gt;&lt;li&gt;Male partner sterilization confirmed and male condom&lt;/li&gt;&lt;li&gt;Approved hormonal contraception and male condom&lt;/li&gt;&lt;li&gt;Any other method with published data showing that the expected failure rate is&amp;lt; 1% per year  and use male condom&lt;/li&gt;&lt;li&gt;Any contraception method must be used for at least 2 weeks after discontinuation of IP&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Genotypic resistance to&lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt; at screening, as per IAS-USA Panel 2013&lt;/li&gt;&lt;li&gt;Alcohol or drug use that might impact on adherence&lt;/li&gt;&lt;li&gt;Patients positive for hepatitis B at screening (+HBsAg), or anticipated need for Hepatitis C virus (HCV) therapy during the study&lt;/li&gt;&lt;li&gt;Lactating, pregnancy or fertile women willing to be pregnant&lt;/li&gt;&lt;li&gt;Concomitant use of lowering lipid drugs, interferon, interleukin-2, cytotoxic chemotherapy, dofetilide (or pilsicainide) or immunosuppressors at study entry&lt;/li&gt;&lt;li&gt;Grade 4 lab abnormalities&lt;/li&gt;&lt;li&gt;Primary HIV infection (indeterminate WB or previous negative HIV in the last 6 months)&lt;/li&gt;&lt;li&gt;Opportunistic infection (CDC C category) or other disease and/or clinical condition that, in the investigator's opinion, would compromise the patient's safety or outcome of the study; including malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia&lt;/li&gt;&lt;li&gt;Patients who in the investigator's judgment, poses a significant suicidality risk&lt;/li&gt;&lt;li&gt;History or presence of allergy to the study drugs or their components or drugs of their class&lt;/li&gt;&lt;li&gt;Treatment with any of the following agents within 28 days of screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses or treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening or exposure to an experimental drug or experimental vaccine within either 28 days,  five half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of investigational product&lt;/li&gt;&lt;li&gt;Any acute laboratory abnormality at  screening, which, in the opinion of the investigator, would preclude the patient's participation in the study of an investigational compound&lt;/li&gt;&lt;li&gt;Alanine aminotransferase (ALT)&amp;gt; 5 x the upper limit of normal (ULN), or ALT   &gt;/= 3 x ULN and bilirubin  &gt;/= 1.5 x ULN (with &amp;gt; 35% direct bilirubin)&lt;/li&gt;&lt;li&gt;Creatinine clearance of&amp;lt; 50 ml/min via Cockcroft-Gault method&lt;/li&gt;&lt;li&gt;Patients with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Efficacy outcome measure: percentage of patients with HIV-1 RNA levels of &lt; 50 copies/ml at week 48 by ITT analysis</Description><Timeframe>48 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Estimation of the viral decay compared to historical data</Description></Measure><Measure><Description>Safety: frequency, type and severity of adverse events and laboratory abnormalities</Description><Timeframe>48 weeks</Timeframe></Measure><Measure><Description>Efficacy: proportion of patients with HIV-1 RNA &lt; 1000 copies/ml at week 12</Description><Timeframe>12 weeks</Timeframe></Measure><Measure><Description>Efficacy: proportion of patients with HIV RNA &lt; 400 copies/ml at week 24</Description><Timeframe>24 weeks</Timeframe></Measure><Measure><Description>Efficacy: changes in CD4+ lymphocyte count between baseline and 48 weeks</Description><Timeframe>48 weeks</Timeframe></Measure><Measure><Description>Number and type of resistance mutations in case of virologic failure (defined as a confirmed viral above 400 copies/mL after week 24 copies/mL or viral rebound at any timepoint)</Description><Timeframe>48 weeks</Timeframe></Measure><Measure><Description>Safety: change in lipid profile between baseline and week 48</Description><Timeframe>48 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the anti-viral efficacy, safety and tolerability of      dual therapy with &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt; (3TC) and &lt;ulink linkType="Drug" linkID="59062"&gt;dolutegravir&lt;/ulink&gt; (DTG) as initial therapy among naive HIV patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="59062"&gt;dolutegravir&lt;/ulink&gt; (50 mg qd) + &lt;ulink linkType="Drug" linkID="3474"&gt;lamivudine&lt;/ulink&gt; (300 mg qd). &lt;br/&gt;&lt;br/&gt;Data collected in this study would  inform the development of larger studies designed to evaluate metabolic and long term safety, impact on inflammatory biomarkers, efficacy, safety and cost effectiveness of this strategy among naïve and suppressed patients. &lt;br/&gt;Primary endpoint: proportion of patients with HIV-1 RNA levels of &amp;lt; 50 copies/ml at week 48.&lt;br/&gt;Secondary endpoints: frequency, type and severity of adverse events and laboratory abnormalities, proportion of patients with HIV-1 RNA &amp;lt; 1000 copies/ml at week 12, proportion of patients with HIV-RNA &amp;lt; 400 at week 24 number and type of resistance mutations in case of virological failure (defined as a confirmed viral above 400 copies/ml after week 24 copies/ml or viral rebound at any timepoint) Changes in CD4+ lymphocyte count between baseline and 48 weeks, estimation of the viral decay compared to historical data.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Argentina"><Sites><Site><Name>Fundacion Huesped</Name><Address1>Caba</Address1><Address2>Buenos Aires</Address2><Address3>C1202ABB</Address3><CountrySubDivision>Buenos Aires</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>HIV infection</Disease><PatientSegments><PatientSegment><PatientSegment id="7308">Subjects with High HIV Viral Load</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19022">Subjects with HIV Infection</PatientSegment><SubSegments><SubSegment id="7126">Subjects with HIV-1 Infection</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02211482</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="HIV infection" id="9212"><Endpoint>Assessment of Viral Load</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9213">Assessment of HIV RNA levels</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="HIV infection" id="9246"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9247">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="HIV infection" id="9208"><Endpoint>Assessment of HIV Resistance</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9210">Assessment of resistant mutations</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="HIV infection" id="9212"><Endpoint>Assessment of Viral Load</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9213">Assessment of HIV RNA levels</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="HIV infection" id="9214"><Endpoint>Assessment of CD4 Cell Responses</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9215">Assessment of CD4 cell count/percentage</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="HIV infection" id="9242"><Endpoint>Assessment of lipid profiles</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="HIV infection" id="5278"><Criterion>Subjects with HIV Infection</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5418">Subjects with HIV-1 infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="5317"><Criterion>Subjects with Protocol Specified HIV Viral Load</Criterion></Inclusion><Inclusion disease="HIV infection" id="5322"><Criterion>Subjects with Protocol Specified CD4+ T Cell Counts </Criterion></Inclusion><Inclusion disease="HIV infection" id="5339"><Criterion>Treatment Naive Subjects</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="HIV infection" id="6843"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6845">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6850"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6851">Subjects with Kaposi's Sarcoma</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6860"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6862">Subjects with abnormal renal function tests</SubCriterion><SubCriterion disease="HIV infection" id="6863">Abnormal liver function test</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6866"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6867">Hypersensitivity/contraindications to nucleoside reverse transcriptase inhibitors</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6892"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="HIV infection" id="6967"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6968">Subjects with prior HIV vaccination</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-03-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>8.03 Months</EnrollmentPeriod><EnrollmentRate>2.49 Patients/Month</EnrollmentRate><DateFirstReceived>2014-08-05T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-08-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-10-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-06-19T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>